{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:47:49Z","timestamp":1782197269389,"version":"3.54.5"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dilated cardiomyopathy (DCM) is a refractory cardiac disease with significant morbidity and mortality. Although immune adsorption combined with immunoglobulin G replacement therapy (IA\/IG) has shown potential in treating DCM, only small-scale clinical trials have been reported. Its efficacy and safety characteristics still need to be further systematically evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis in accordance with PRISMA 2020 guidelines. A comprehensive search of PubMed, Embase, Web of Science, and the Cochrane Library was performed up to July 1, 2025. Clinical studies on IA\/IG treatment for DCM were included. The primary outcome was the left ventricular ejection fraction (LVEF) change. Secondary outcomes included left ventricular end-diastolic dimension (LVEDD), NYHA functional class, N-terminal pro-brain natriuretic peptide (NT-proBNP), and VO2 peak. Study quality and risk of bias were assessed using the Cochrane ROB 2.0 and ROBINS-I tools. Sensitivity analysis was taken into consideration to determine the stability of the results. This review was registered with PROSPERO (CRD420251104796).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighteen studies (2 RCTs and 16 non-RCTs) involving 809 participants were included. IA\/IG therapy significantly improved LVEF [mean difference (MD)\u2009=\u20097.71%, 95% CI: 6.18\u20139.24,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.00001] and reduced LVEDD (MD\u2009=\u2009\u22123.22\u2005mm, 95% CI: \u22124.16 to \u22122.28,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.00001) from baseline. Significant improvements were also observed in NYHA functional class (MD\u2009=\u2009\u22120.76, 95% CI: \u22120.91 to \u22120.60,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.00001) and peak VO\u2082 (MD\u2009=\u20092.66\u2005mL\/kg\/min, 95% CI: 1.26\u20134.06,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0002). Compared to controls, the IA\/IG group demonstrated greater improvement in LVEF (MD\u2009=\u20098.31%, 95% CI: 6.45\u201310.18,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.00001) and NYHA class (MD\u2009=\u2009\u20130.62, 95% CI: \u22121.00 to \u22120.25,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). A sensitivity analysis of the results suggested that they were stable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Systematic reviews and meta-analyses suggest that IA\/IG therapy may improve cardiac function and quality of life in patients with DCM. However, the number of RCTs included in the study is limited, so these results should be interpreted with caution. Further high-quality, large-scale trials are warranted to establish standardized treatment protocols and confirm the long-term benefits of IA\/IG therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/recorddashboard<\/jats:ext-link>\n                      , PROSPERO CRD420251104796.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1840280","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:11:59Z","timestamp":1782195119000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunoadsorption and subsequent immunoglobulin G replacement (IA\/IG) in patients with dilated cardiomyopathy: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiao","family":"Xia","sequence":"first","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Graduate School of China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Yao","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Tao","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanchun","family":"Huang","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Graduate School of China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Meng","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiying","family":"Liu","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Graduate School of China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghao","family":"Li","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruikang","family":"Liu","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]},{"name":"Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(23)01241-2","article-title":"Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches","volume":"402","author":"Heymans","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.rec.2022.05.005","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the exceptional contribution of the Heart Failure Association (HFA) of the ESC","volume":"75","author":"McDonagh","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1161\/CIR.0000000000000455","article-title":"Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association","volume":"134","author":"Bozkurt","year":"2016","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 81 1 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Diseases","year":"2024","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1161\/CIRCULATIONAHA.120.050812","article-title":"LARP7 Protects against heart failure by enhancing mitochondrial biogenesis","volume":"143","author":"Yu","year":"2021","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41569-024-01074-2","article-title":"Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine","volume":"22","author":"Gigli","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/ehjqcco\/qcae109","article-title":"Diagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendations","volume":"11","author":"Sorella","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.3390\/ijms26104550","article-title":"Influence of soluble guanylate cyclase on cardiac, vascular, and renal structure and function: a physiopathological insight","volume":"26","author":"De Feo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1429405","DOI":"10.3389\/fimmu.2024.1429405","article-title":"Protein-A immunoadsorption combined with immunosuppressive treatment in refractory primary Sj\u00f6gren's syndrome coexisting with NMOSD: a case report and literature review","volume":"15","author":"Fan","year":"2024","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1007\/s10067-020-05156-7","article-title":"Meta-analysis on the efficacy and safety of immunoadsorption for syste mic lupus erythematosus among Chinese population","volume":"39","author":"Yang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e16230","DOI":"10.1111\/ene.16230","article-title":"Response to letter on European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome","volume":"31","author":"Van Doorn","year":"2024","journal-title":"Eur J Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/jca.21446","article-title":"Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column: a prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety","volume":"31","author":"Yoshikawa","year":"2016","journal-title":"J Clin Apher"},{"key":"B13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1161\/01.CIR.101.4.385","article-title":"Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy","volume":"101","author":"M\u00fcller","year":"2000","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.atherosclerosissup.2015.02.023","article-title":"Immunoadsorption can improve cardiac function in transplant candidates with non-ischemic dilated cardiomyopathy associated with diabetes mellitus","volume":"18","author":"Dandel","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"B15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00392-011-0287-2","article-title":"Effects of immunoadsorption on endothelial function, circulating endothelial progenitor cells and circulating microparticles in patients with inflammatory dilated cardiomyopathy","volume":"100","author":"Bulut","year":"2011","journal-title":"Clin Res Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.CIR.93.5.841","article-title":"Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies","volume":"93","author":"Richardson","year":"1996","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Br Med J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1161\/01.CIR.103.22.2681","article-title":"Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution","volume":"103","author":"Staudt","year":"2001","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0735-1097(00)00568-4","article-title":"Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study","volume":"35","author":"Felix","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1093\/eurjhf\/hfs123","article-title":"Long-term benefits of immunoadsorption in \u03b21-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy","volume":"14","author":"Dandel","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"B23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ahj.2010.01.012","article-title":"Effects of immunoadsorption and subsequent immunoglobulin G substitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy","volume":"159","author":"Herda","year":"2010","journal-title":"Am Heart J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1744-9987.2006.00343.x","article-title":"Effects of immunoadsorption on the nt-BNP and nt-ANP plasma levels of patients suffering from dilated cardiomyopathy","volume":"10","author":"Staudt","year":"2006","journal-title":"Ther Apher Dial"},{"key":"B25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00395-010-0096-1","article-title":"Lack of evidence for a pathogenic role of proteasome-directed autoimmunity in dilated cardiomyopathy","volume":"105","author":"Voigt","year":"2010","journal-title":"Basic Res Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/clpt.2009.246","article-title":"Fc\u03b3-receptor IIa polymorphism and the role of immunoadsorption in cardiac dysfunction in patients with dilated cardiomyopathy","volume":"87","author":"Staudt","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/jca.21364","article-title":"The effect of a repeated immunoadsorption in patients with dilated cardiomyopathy after recurrence of severe heart failure symptoms","volume":"30","author":"Reinthaler","year":"2014","journal-title":"J Clin Apher"},{"key":"B28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jprot.2016.09.001","article-title":"Endomyocardial proteomic signature corresponding to the response of patients with dilated cardiomyopathy to immunoadsorption therapy","volume":"150","author":"Bhardwaj","year":"2017","journal-title":"J Proteomics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ijcard.2003.12.003","article-title":"Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy","volume":"97","author":"Knebel","year":"2004","journal-title":"Int J Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00109-007-0263-5","article-title":"Immunoadsorption and subsequent immunoglobulin substitution decreases myocardial gene expression of desmin in dilated cardiomyopathy","volume":"85","author":"Kallwellis-Opara","year":"2007","journal-title":"J Mol Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/j.1365-2362.2010.02314.x","article-title":"Immunoadsorption in dilated cardiomyopathy: long-term reduction of cardiodepressant antibodies","volume":"40","author":"Trimpert","year":"2010","journal-title":"Eur J Clin Investig"},{"key":"B32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jjcc.2016.07.014","article-title":"Therapeutic effect of immunoadsorption and subsequent immunoglobulin substitution in patients with dilated cardiomyopathy: results from the observational prospective Bad Berka Registry","volume":"69","author":"Ohlow","year":"2017","journal-title":"J Cardiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/jca.20263","article-title":"Effects of protein A immunoadsorption in patients with chronic dilated cardiomyopathy","volume":"25","author":"Doesch","year":"2010","journal-title":"J Clin Apher"},{"key":"B34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1590\/1806-9282.20220784","article-title":"Immunoadsorption therapy in refractory heart failure patients with dilated cardiomyopathy: a potential therapeutic option","volume":"69","author":"Cavusoglu","year":"2023","journal-title":"Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"},{"key":"B35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/sji.12000","article-title":"The number of regulatory T cells correlates with hemodynamic improvement in patients with inflammatory dilated cardiomyopathy after immunoadsorption therapy","volume":"77","author":"Bulut","year":"2012","journal-title":"Scand J Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/eurheartj\/ehs330","article-title":"Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy","volume":"34","author":"Ameling","year":"2013","journal-title":"Eur Heart J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e26475","DOI":"10.1097\/MD.0000000000026475","article-title":"Immunoadsorption treatment for dilated cardiomyopathy: a PRISMA-compliant systematic review and meta-analysis","volume":"100","author":"Bian","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"103755","DOI":"10.1016\/j.autrev.2025.103755","article-title":"Frequency of autoantibodies and their associated clinical characteristics and outcomes in patients with dilated cardiomyopathy: a systematic review and meta-analysis","volume":"24","author":"Zhang","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2741\/4709","article-title":"Functional autoantibody diseases: basics and treatment related to cardiomyopathies","volume":"24","author":"Becker","year":"2019","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e006155","DOI":"10.1161\/CIRCHEARTFAILURE.119.006155","article-title":"\u03b21-Adrenoreceptor autoantibodies in heart failure. Physiology and therapeutic implications","volume":"13","author":"D\u00fcngen","year":"2020","journal-title":"Circ Heart Fail"},{"key":"B41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cardfail.2008.02.016","article-title":"Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy","volume":"14","author":"Lapp\u00e9","year":"2008","journal-title":"Card Fail"},{"key":"B42","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41420-021-00735-2","article-title":"Biased activation of \u03b21-AR\/gi\/GRK2 signal pathway attenuated \u03b21-AR sustained activation induced by \u03b21-adrenergic receptor autoantibody","volume":"7","author":"Chen","year":"2021","journal-title":"Cell Death Discov"},{"key":"B43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12872-020-01492-3","article-title":"\u03921 adrenoceptor antibodies induce myocardial apoptosis via inhibiting PGC-1\u03b1-related pathway","volume":"20","author":"Shi","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"B44","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/jcm14030947","article-title":"Autoimmunity in cardiomyopathy-induced heart failure and cardiac autoantibody removal by immunoadsorption","volume":"14","author":"Dandel","year":"2025","journal-title":"J Clin Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jaci.2013.08.042","article-title":"Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells","volume":"133","author":"S\u00e9\u00eft\u00e9","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41392-025-02143-9","article-title":"Spatiotemporal transcriptomics elucidates the pathogenesis of fulminant viral myocarditis","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S0735-1097(01)01309-2","article-title":"Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption","volume":"38","author":"Schimke","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"103386","DOI":"10.1016\/j.autrev.2023.103386","article-title":"Functional autoantibodies: definition, mechanisms, origin and contributions to autoimmune and non-autoimmune disorders","volume":"22","author":"Yu","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1056\/NEJM200211283472220","article-title":"Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy","volume":"347","author":"Wallukat","year":"2002","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1742-7843.2005.pto_96607.x","article-title":"Effects of immunoglobulin G from patients with dilated cardiomyopathy on rat cardiomyocytes","volume":"96","author":"Christ","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12933-025-02690-z","article-title":"The adverse effect of metabolic syndrome on left ventricular global strains and myocardial energetic efficiency in non-ischemic dilated cardiomyopathy patients: a cardiac magnetic resonance study","volume":"24","author":"Shen","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"284","DOI":"10.2459\/JCM.0000000000001733","article-title":"Impact of SGLT2 inhibitors on endothelial function and echocardiographic parameters in dilated cardiomyopathy","volume":"26","author":"Cersosimo","year":"2025","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1010-7940(03)00002-2","article-title":"MRI Evaluation of left ventricular function in anterior LV aneurysms b efore and after surgical resection","volume":"23","author":"Versteegh","year":"2003","journal-title":"Eur J Cardiothorac Surg"},{"key":"B54","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apher"},{"key":"B55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejphar.2016.06.061","article-title":"Aptamer BC 007 - A broad spectrum neutralizer of pathogenic autoantibodies against G-protein-coupled receptors","volume":"789","author":"Haberland","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1161\/01.CIR.0000036746.49449.64","article-title":"Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy","volume":"106","author":"Staudt","year":"2002","journal-title":"Circulation"},{"key":"B57","doi-asserted-by":"publisher","first-page":"463652","DOI":"10.1016\/j.chroma.2022.463652","article-title":"Effect of solution condition on the binding behaviors of monoclonal antibody and fusion protein therapeutics in protein A chromatography","volume":"1686","author":"Guo","year":"2022","journal-title":"J Chromatogr A"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jca.20268","article-title":"Specific immunoadsorption therapy using a tryptophan column in patients with refractory heart failure due to dilated cardiomyopathy","volume":"26","author":"Nagatomo","year":"2011","journal-title":"J Clin Apher"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1002\/ejhf.3476","article-title":"Multicentre, randomized, double-blind, prospective study on the effect s of ImmunoAdSorptiOn on cardiac function in patients with dilated CardioMyopathy (IASO-DCM): rationale and design","volume":"26","author":"D\u00f6rr","year":"2024","journal-title":"Eur J Heart Fail"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1840280\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:12:00Z","timestamp":1782195120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1840280\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":59,"alternative-id":["10.3389\/fcvm.2026.1840280"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1840280","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1840280"}}